Celularity Inc
For the period ended Dec 31, 2023. Filed Jul 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Jul 30, 2024
CELU$0.76-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $227 | $13,966 |
| Accounts receivable, net of allowance of $5,837 and $1,789 as of December 31, 2023 and December 31, 2022, respectively | 10,046 | 4,452 |
| Notes receivable | 2,072 | 2,514 |
| Inventory | 5,753 | 5,308 |
| Prepaid expenses and other current assets | 1,695 | 7,262 |
| Total current assets | 19,793 | 33,502 |
| Property and equipment, net | 67,828 | 75,655 |
| Goodwill | 7,347 | 119,694 |
| Intangible assets, net | 11,001 | 120,994 |
| Right-of-use assets - operating leases | 10,990 | 13,060 |
| Restricted cash | 9,936 | 14,836 |
| Inventory, net of current portion | 16,657 | 22,949 |
| Other long-term assets | 337 | 376 |
| Total assets | $143,889 | $401,066 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $14,144 | $5,810 |
| Accrued expenses and other current liabilities | 7,580 | 9,069 |
| Accrued R&D software | 3,500 | 7,333 |
| Short-term debt - Yorkville ($17,223 at fair value and $16,623 unpaid principal balance at December 31, 2023 and $37,603 at fair value and $37,000 unpaid principal balance at December 31, 2022) | 17,223 | 37,603 |
| Other short-term debt | 2,108 | — |
| Short-term debt - related party | 1,419 | — |
| Short-term debt - related parties - C.V. Starr and RWI | 18,490 | — |
| Deferred revenue | 2,834 | 2,273 |
| Total current liabilities | 67,298 | 62,088 |
| Deferred revenue, net of current portion | 3,186 | 2,219 |
| Acquisition-related contingent consideration | 1,606 | 105,945 |
| Noncurrent lease liabilities - operating | 26,177 | 27,985 |
| Warrant liabilities | 4,359 | 3,598 |
| Deferred income tax liabilities | 9 | 9 |
| Other liabilities | 294 | 321 |
| Total liabilities | 102,929 | 202,165 |
| Commitments and Contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2023 and December 31, 2022 | — | — |
| Common Stock, $0.0001 par value, 730,000,000 shares authorized, 19,378,192 issued and outstanding as of December 31, 2023; 730,000,000 shares authorized, 14,892,129 issued and outstanding as of December 31, 2022 | 19 | 15 |
| Additional paid-in capital | 882,732 | 844,373 |
| Accumulated other comprehensive income | - | 9 |
| Accumulated deficit | (841,791) | (645,496) |
| Total stockholders’ equity | 40,960 | 198,901 |
| Total liabilities and stockholders’ equity | $143,889 | $401,066 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.